Adma Biologics (ADMA) Non-Current Assets (2011 - 2026)
Adma Biologics' (ADMA) quarterly Non-Current Assets came in at $157.7 million in Q4 2025, little changed YoY from $157.3 million in Q4 2024, and down 5.0% on a QoQ basis from $166.0 million in Q3 2025.
Adma Biologics (ADMA) Non-Current Assets (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Non-Current Assets data on file, last reported at $157.7 million in Q4 2025.
- Quarterly Non-Current Assets changed 0.29% year-over-year to $157.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $641.3 million (up 70.18% YoY) and the FY2025 annual result came in at $157.7 million, changed 0.29% from the prior year.
- Non-Current Assets slipped to $157.7 million in Q4 2025, from $166.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $166.0 million in Q3 2025 to a low of $58.4 million in Q1 2021.
- A 5-year average of $93.4 million and a median of $74.9 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets soared 189.85% — and 2023, when it slipped 7.55%.
- Tracing ADMA's Non-Current Assets over 5 years: stood at $67.5 million in 2021, then rose by 15.6% to $78.1 million in 2022, then decreased by 7.55% to $72.2 million in 2023, then jumped by 117.92% to $157.3 million in 2024, then gained by 0.29% to $157.7 million in 2025.
- The last three Non-Current Assets figures came in at $157.7 million (Q4 2025), $166.0 million (Q3 2025), and $158.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 156.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.01 Mn |
| Dec 31, 2025 | 157.73 Mn |
| Sep 30, 2025 | 166.03 Mn |
| Jun 30, 2025 | 158.82 Mn |
| Mar 31, 2025 | 158.76 Mn |
| Dec 31, 2024 | 157.27 Mn |
| Sep 30, 2024 | 72.43 Mn |
| Jun 30, 2024 | 72.71 Mn |
| Mar 31, 2024 | 74.46 Mn |
| Dec 31, 2023 | 72.17 Mn |
| Sep 30, 2023 | 75.30 Mn |
| Jun 30, 2023 | 76.78 Mn |
| Mar 31, 2023 | 76.70 Mn |
| Dec 31, 2022 | 78.06 Mn |
| Sep 30, 2022 | 76.46 Mn |
| Jun 30, 2022 | 74.16 Mn |
| Mar 31, 2022 | 68.23 Mn |
| Dec 31, 2021 | 67.52 Mn |
| Sep 30, 2021 | 63.86 Mn |
| Jun 30, 2021 | 61.46 Mn |